By: mind31
14 Jan 2004, 01:58 PM EST
Msg. 134942 of 134942
Jump to msg. #  
"We have not registered the resale of a sufficient number of shares of common stock in this offering to fully draw down the $50 million available under the Equity Line of Credit. At an assumed offering price of $0.08 per share, we would only be able to draw a total gross amount of $7,657,008
under the Equity Line of Credit using all of the 95,712,595 shares being registered in this offering. Based on an assumed offering price of $0.08 per share, we would need to issue 625,000,000 shares of common stock to draw the entire $50 million available under the Equity Line of Credit. If the price of our common stock decreased to $0.04 per share we would need 1,250,000,000 shares of common stock to draw the entire $50 million available under the Equity Line of Credit. Based on the 544,591,722 shares of stock currently outstanding, we do not have sufficient authorized shares of common stock to draw down the entire $50 million available under the Equity Line of Credit at an assumed stock price of either $0.08 or $0.04 per share. To increase the number of authorized shares of our common stock, we would need to obtain stockholder approval. We are uncertain that we could obtain this approval based on the dilutive effect of the issuance of shares under the Equity Line of Credit. Additionally, we would need to file another registration statement to cover any shares under the Equity Line of
Credit other than the 95,712,595 being registered in this registration statement."

IAG
By: michaelclark11
14 Jan 2004, 05:41 PM EST
Msg. 135011 of 135055
Jump to msg. #  
At the beginning of the article, it states in the Company Brief: (Nasdaq:ADVR;www.adviral.com)

Are we on the Nasdaq now, or was this a typo?

Either way, the entire article is fantastic news. They're currently in discussions with Pharma's, and talk of Fast Track and Phase II/III trials. On the markert within 4yrs.(that's not taking into consideration getting Fast Tracked)

Great things are going to happen in the future. I'm loading up on this one.

By: FoxChase1803
14 Jan 2004, 05:41 PM EST
Msg. 135010 of 135055
Jump to msg. #  
A solution for body wasting

Updated: 1/7/2004
By: Emily Schmitz

Eric Blanchette takes human growth hormone to fight body wasting syndrome.

People who are HIV-positive are living longer today than they did just a decade ago.

Research shows people taking the highly active anti-retroviral treatment, or HAART therapy, live an average of 11 years after they're diagnosed.

Eric Blanchette is beating those odds. He was diagnosed with HIV 23 years ago. He takes four medications a day.

But living this long with the disease and taking the very medications that keep him alive come with a cost.

He suffers from a condition called body wasting syndrome where his body starts to metabolize his own body fat and protein.

"I also started noticing in my extremities that I was able to see my veins and things that I didn't see before," Blanchette said.

Dr. David Wright's been treating Eric for the last five years.

"What you really want to see if an increase of lean body mass or an increase in protein stores," Wright said.

The solution for Blanchette was taking hormones.

"I went on human growth hormone which was very successful. The results were dramatic," he said.

Human growth hormone is the standard treatment for body wasting. But patients can only stay on that for about 12 weeks. There are some side effects and it costs more than $20,000 for each course of treatment.

Researchers in New York have high hopes on a more effective and less expensive treatment for body wasting. They're studying a drug called AVR-118. It's about a tenth of the cost of human growth hormones. And initial studies are showing great promise.

"In a non-toxic way, it can help patients get through their treatment and gain weight and improve their quality of life," said Dr. James D'Olimpio, a palliative medicine specialist.


Blanchette is optimistic about the research in New York. But he said his current side effects are a small price to pay to be alive.

www.news8austin.com

By: FoxChase1803
14 Jan 2004, 05:47 PM EST
Msg. 135014 of 135055
(This msg. is a reply to 135010 by FoxChase1803.)
Jump to msg. #  
"Researchers in New York have high hopes on a more effective and less expensive treatment for body wasting. They're studying a drug called AVR-118. It's about a tenth of the cost of human growth hormones. And initial studies are showing great promise.

"In a non-toxic way, it can help patients get through their treatment and gain weight and improve their quality of life," said Dr. James D'Olimpio, a palliative medicine specialist."

http://ragingbull.lycos.com/mboard/boards.cgi?board=ADVR&read=135010

By: FoxChase1803
14 Jan 2004, 05:57 PM EST
Msg. 135018 of 135055
(This msg. is a reply to 135014 by FoxChase1803.)
Jump to msg. #  
"They're studying a drug called AVR118."

http://news8austin.com/content/living/health_beat/?SecID=169&ArID=94310
- - - - -

the link from above is shown below.

 

 

Pedernales Electric delivers electric service to more members than any cooperative in Texas. Digital Video Recorder Menopause The Musical
News 8 AustinYour News NowYour News NowAn Exclusive Service of Time Warner Cable
News 8 Austin


TOP STORIES


HEADLINES


LOCAL NEWS


YOUR NEWS


WEATHER


SPORTS


LIVING


8 Outdoors


Backstage Pass


Center Stage


Dinner at 8


Fashionably 8


Golf Tips


Health Beat


Home at 8


Live Wire


Mrs. Fixit


On the Safe Side


Out in the Garden


Parenting


Pet Vet


Sports Doc


Summer Music


Texas Road Trip


Turn Back the Clock


Web Sightings


NEWS 8 EXPLORES


SPECIAL COVERAGE


COMMUNITY


COMMENTARY


ABOUT US


SEARCH


NEWS8CAST VIDEO


Keep Austin Warm

Fertile Hope 5K

Contact News 8 through the IVC.

Click here for recent reviews.

Health Beat

6 36 am

x59
A solution for body wasting
1/7/2004 5:00 AM
By: Emily Schmitz

Eric Blanchette takes human growth hormone to fight body wasting syndrome.  
People who are HIV-positive are living longer today than they did just a decade ago.

Research shows people taking the highly active anti-retroviral treatment, or HAART therapy, live an average of 11 years after they're diagnosed.

Eric Blanchette is beating those odds. He was diagnosed with HIV 23 years ago. He takes four medications a day.

But living this long with the disease and taking the very medications that keep him alive come with a cost.

He suffers from a condition called body wasting syndrome where his body starts to metabolize his own body fat and protein.

"I also started noticing in my extremities that I was able to see my veins and things that I didn't see before," Blanchette said.

 WATCH THE VIDEO
More Information
Growth hormones

Growth hormones have been successful to stop body wasting from anti-HIV medications.



Dr. David Wright's been treating Eric for the last five years.

"What you really want to see if an increase of lean body mass or an increase in protein stores," Wright said.

The solution for Blanchette was taking hormones.

"I went on human growth hormone which was very successful. The results were dramatic," he said.

Human growth hormone is the standard treatment for body wasting. But patients can only stay on that for about 12 weeks. There are some side effects and it costs more than $20,000 for each course of treatment.

Researchers in New York have high hopes on a more effective and less expensive treatment for body wasting. They're studying a drug called AVR-118. It's about a tenth of the cost of human growth hormones. And initial studies are showing great promise.

"In a non-toxic way, it can help patients get through their treatment and gain weight and improve their quality of life," said Dr. James D'Olimpio, a palliative medicine specialist.

Blanchette is optimistic about the research in New York. But he said his current side effects are a small price to pay to be alive.





Seven days a week News 8 Austin’s Health Beat brings you reports on health care, treatments and medical news from our community facilities and from around the nation.




Email this Story to a Friend
Printer Friendly Version
Search Health Beat



Weather Center
daytime
1/15/2004
Near 60
evening
1/15/2004
Near 60
overnight
1/16/2004
Upper 50s
Online Poll

What do you think of President Bush's plan to to send men back to the Moon and to Mars?
To the moon, Alice!
I think we need to worry about the earth first.
This is just a political distraction.
What about Saddam?
Other.

VoteView Results

Direct to your Inbox:
• Top Stories
• Breaking News
• Weather Alerts
Please visit our subscription homepage for the details.


Health Beat

After a stroke...

Furniture worth staying home for.
In Other News

Internet Exploitation Investigation Van...

Wheel and rim theft...

'Coral Reef Adventure'...

Voting district 25...

Phillipses settle with Deputy Taylor...

 

Home | Terms of Use | Privacy Policy | Contact Information
Copyright ©2004TWEAN News Channel of Austin, L.P. d.b.a. News 8 Austin


 


Digital Cable offers the latest in home-viewing entertainment.
Customer self-help information
Time Warner Cable now offers you more choices in High Speed Internet service.
Time Warner Digital Cable offers a wide variety of commercial products designed to accelerate the growth of your business.
Video On Demand lets you instantly choose from a wide selection of great movies and award- winning programming.
Digital Cable channel lineups.
Time Warner Cable's event calendar.
TV listings for your service area.
Take a look at the special offers and promotions available now through Time Warner Cable Austin.
Effective and affordable local advertising on over 40 cable television networks.


See the DVR-8000 product demo and take control of your TV!
When in San Antonio, watch News 9 San Antonio on Time Warner Cable.
Movie premieres on Time Warner Cable's Movies-on-Demand
Rangers and Astros on Time Warner Cable.
High-Def TV on Time Warner Cable.
tower ad space

By: Ourobouros
14 Jan 2004, 07:36 PM EST
Msg. 135028 of 135055
(This msg. is a reply to 134952 by billblueyz.)
Jump to msg. #  
No scan necessary, just cut and paste::

-----------------------------

42 LEADERS POSTED WITH PERMISSION. COPYRIGHT © LEADERS

An Interview with Eli Wilner, Chairman, and James T. D'Olimpio, M.D., Member,
Scientific Advisory Board, and Spokesperson at Large, Advanced Viral Research Corp., Yonkers, New York
Eli Wilner James T. D'Olimpio

INTERVIEW

A Life-Changing Drug?

EDITORS? NOTE A past Bryant Fellow of the Metropolitan Museum of Art, Eli Wilner holds a B.A. from Brandeis University and an M.A. from Hunter College. Dr. James D'Olimpio, who is triple board certified in internal medicine, medical oncology, and hospice/palliative medicine, is also director of supportive
oncology and the Palliative Care/Cancer Pain Service at North Shore University Hospital in Manhasset, New York, as well as an assistant professor at New York University's medical school. COMPANY BRIEF Headquartered in metropolitan New York, Advanced Viral Research Corp. (Nasdaq: ADVR;
www.adviral.com) is a biopharmaceutical firm dedicated to improving people's lives by developing and bringing to market new effective therapies for viral and other diseases.

Its primary involvement at present is its peptide-nucleic acid AVR118, now in clinical trials in Israel for the treatment of cachexia, or body wasting, in patients with AIDS.You've reported quite a remarkable breakthrough in the battle against AIDS. Please elaborate. D'Olimpio: The group we've assembled is basically trying to improve the quality of life of patients suffering from HIV disease. Now, there are many elements to that, the most important being the experience that patients endure while they're receiving treatment. Treatments are much
more successful than they used to be, but a significant number of patients still suffer the ill effects of treatments along with the effects of the disease. Cancer patients suffer in similar ways from toxic therapies.


As it stands now, our company has developed the platform of a very sophisticated technology ? a series of proteins put together in what's called a peptide-nucleic acid complex. The clinical manifestation
of this particular complex is in modulating the immune system. When the patients with HIV disease we've been working with in Israel started to take our Product R, or AVR118, in clinical trials, the preliminary results were such that every patient experienced a positive clinical benefit. Now, a positive clinical benefit is
sometimes difficult to describe. What it means is that each patient told his doctor he was feeling better. That's the bottom line. They feel as if the treatment they're receiving for HIV disease is actually helping them. They're feeling as if their quality of life has improved to the extent that they'll continue with treatment.


In addition, our study was designed to measure weight loss. Patients with HIV disease receiving hard therapy ? chemotherapy, really ? frequently experience weight loss from both the treatment and the disease itself. But when AVR118 was given to the patients, every one either gained weight or stabilized his existing weight. So, the actual thickness of their muscles and fat tissue was measured, their quality of life was measured, and both improved.
When this happened, we were somewhat stunned. I sit on the scientific advisory board of Advanced Viral Research along with some quite important people in the field, and we certainly were surprised
that every patient responded, firstly. And secondly, they responded without any serious adverse events. In other words, there was no toxicity to this study. Had we been conducting our trials in the United States instead of Israel, the FDA would have required us to increase the dosage of the drug 10 times to prove no significant change in toxicity or any adverse events. We did this successfully, and, what is more, patients on the 10-fold
dosage felt even better. That is, the higher the dosage, the more striking the results. Now, we?re putting this data together in a statistical format, so we can present it to the scientific and medical communities for appropriate scrutiny and peer review.


When will AVR118 be available in the United States? D?Olimpio: Fortunately, the Israeli government was willing to use the exact same process that we would have used for FDA approval. Thus, we believe we?ll have
a significant clinical basis for proceeding on a fast track to get this drug approved in the United States.
And what will this mean for your company?
Wilner: At the moment our company has a market cap of over $100 million. Once the drug goes through Phase II trials in America and shows promising results, there will be an increase in our valuation. And a really large increase in valuation should occur after a Phase III trial, which should be in about three years. By 2007 or 2008,
AVR118 should be on the market, as long as it keeps proving its efficacy and safety.


If AVR118 is as successful as you feel, a large pharmaceutical firm should want to acquire it. Wilner: We're in discussions right now with several companies about licensing segments of our drug, and because it
addresses so many disease states, we'lll most likely partner with several. There are actually other aspects of our
drug that potential investors should consider. Several specialists have told me that it's the easiest drug to manufacture they've ever seen. It's also extremely inexpensive to produce, and it has a very long shelf life ?
more than two years thus far at room temperature, which is very good for developing countries without widespread refrigeration. 

Plus, it has protection under a very strong patent, issued in March 2003 for 17 years.
My friends, my family, and I have more than $4 million in this company, and we're
extremely excited about its prospects.?